Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal ...
Koelis, SAS (“Koelis” or the “Company”, a global leader and innovator in prostate care, announced today passing an important milestone demonstrating the value of its Koelis Trinity 3D Ultrasound ...